VWWMG
BBIO icon

Vermillion & White Wealth Management Group’s BridgeBio Pharma BBIO Stock Holding History

Vermillion & White Wealth Management Group’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-93
Closed -$7.11K – 114
2025
Q4 		$7.11K Hold
93
– – ﹤0.01% 361
2025
Q3 		$4.83K Hold
93
– – ﹤0.01% 421
2025
Q2 		$4.02K Buy
+93
New +$3.38K ﹤0.01% 422

Other funds holding BBIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vermillion & White Wealth Management Group's BBIO Position: Q1 2026 in Review

Vermillion & White Wealth Management Group sold out of BridgeBio Pharma (BBIO) in Q1 2026, closing a stake of 93 shares — an estimated $7.11K sold.

Vermillion & White Wealth Management Group first reported a position in BBIO in Q2 2025 and held it in 3 quarters. The position peaked at $7.11K in Q4 2025. 460 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Vermillion & White Wealth Management Group reported no remaining BridgeBio Pharma position as of Q1 2026 after selling out during the quarter.
  • Vermillion & White Wealth Management Group sold 93 BridgeBio Pharma shares in Q1 2026, an estimated $7.11K.
  • Vermillion & White Wealth Management Group first reported a position in BridgeBio Pharma in Q2 2025 and held it in 3 quarters.
  • Vermillion & White Wealth Management Group's BridgeBio Pharma position peaked at $7.11K in Q4 2025.
  • 460 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Vermillion & White Wealth Management Group's 13F filing for Q1 2026, filed 14 May 2026.